Efficacy and Safety of Low-Dose Intravesical OnabotulinumtoxinA Injections in Female Patients With Detrusor Overactivity With Detrusor Underactivity
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: We assessed the effectiveness and safety of using intravesical onabotulinumtoxinA (onabotA; BOTOX) injection with a low dose (75 units) for treating urinary storage symptoms in patients with detrusor overactivity with detrusor underactivity (DODU) compared to using the standard 100 units of onabotA in patients with overactive bladder (OAB).Methods: This ambidirectional study included 121 female patients who received intravesical onabotA injections at our hospitals. A total of 87 patients with OAB and 34 patients with DODU were reviewed using a 3-day voiding diary, uroflowmetry, and questionnaires including the International Prostate Symptom Score (IPSS), Overactive Bladder Symptom Score, and Patient Perception of Bladder Condition. Patients were evaluated at baseline, within 2 weeks of treatment, and beyond 3 months after treatment.Results: Questionnaire scores of the DODU group demonstrated significant improvement in the short term, with a subsequent decline, but an overall improvement compared to baseline in the long term. Notably, the DODU group exhibited enhanced IPSS voiding scores after the treatment. In the OAB group, most questionnaire scores, excluding the IPSS voiding score, showed significant posttreatment improvement, which was sustained to some extent in the long term. Voiding diary parameters related to storage symptoms were enhanced in both groups. The maximum and mean flow rates decreased in the OAB group but increased in the DODU group, particularly in the short term (P=0.000). The postvoid residual volume increased in both groups after posttreatment, with a mitigated change in the long term. Safety assessments revealed manageable adverse events in both groups with comparable frequencies.Conclusions: Low-dose intravesical onabotA for DODU demonstrated a relatively shorter duration of efficacy than OAB. Nonetheless, the treatment improved both storage and voiding symptoms in patients with DODU without significant adverse effects.
Abstract
Purpose: We assessed the effectiveness and safety of using intravesical onabotulinumtoxinA (onabotA; BOTOX) injection with a low dose (75 units) for treating urinary storage symptoms in patients with detrusor overactivity with detrusor underactivity (DODU) compared to using the standard 100 units of onabotA in patients with overactive bladder (OAB).Methods: This ambidirectional study included 121 female patients who received intravesical onabotA injections at our hospitals. A total of 87 patients with OAB and 34 patients with DODU were reviewed using a 3-day voiding diary, uroflowmetry, and questionnaires including the International Prostate Symptom Score (IPSS), Overactive Bladder Symptom Score, and Patient Perception of Bladder Condition. Patients were evaluated at baseline, within 2 weeks of treatment, and beyond 3 months after treatment.Results: Questionnaire scores of the DODU group demonstrated significant improvement in the short term, with a subsequent decline, but an overall improvement compared to baseline in the long term. Notably, the DODU group exhibited enhanced IPSS voiding scores after the treatment. In the OAB group, most questionnaire scores, excluding the IPSS voiding score, showed significant posttreatment improvement, which was sustained to some extent in the long term. Voiding diary parameters related to storage symptoms were enhanced in both groups. The maximum and mean flow rates decreased in the OAB group but increased in the DODU group, particularly in the short term (P=0.000). The postvoid residual volume increased in both groups after posttreatment, with a mitigated change in the long term. Safety assessments revealed manageable adverse events in both groups with comparable frequencies.Conclusions: Low-dose intravesical onabotA for DODU demonstrated a relatively shorter duration of efficacy than OAB. Nonetheless, the treatment improved both storage and voiding symptoms in patients with DODU without significant adverse effects.
참고문헌 (21)
- Abrams P, "The standardisation of terminology of lower urinary tract function : report from the standardisation sub-committee of the International Continence Society", Neurourol Urodyn, 21, pp.167~178 (2002)
- Yalla SV, "Update on detrusor hyperactivity with impaired contractility", Curr Bladder Dysfunct Rep, 2, pp.191~196 (2007)
- Brown CT, "Detrusor underactivity and detrusor hyperactivity with impaired contractility", Curr Bladder Dysfunct Rep, 9, pp.341~349 (2014)
- Kuo HC, "Urodynamic evidence of effectiveness of botulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents", Urology, 63, pp.868~872 (2004)
- Kuo YC, "Botulinum toxin injection for lower urinary tract dysfunction", Int J Urol, 20, pp.40~55 (2013)
- Liao CH, "Increased risk of large post-void residual urine and decreased long-term success rate after intravesical onabotulinumtoxinA injection for refractory idiopathic detrusor overactivity", J Urol, 189, pp.1804~1810 (2013)
- Wang CC, "Efficacy and safety of intravesical onabotulinumtoxinA injection in patients with detrusor hyperactivity and impaired contractility", Toxins(Basel), 8, pp.82~ (2016)
- Wang CC, "Videourodynamics identifies the causes of young men with lower urinary tract symptoms and low uroflow", Eur Urol, 4, pp.386~390 (2003)
- Nitti VW, "Lower urinary tract symptoms in young men : video urodynamic findings and correlation with noninvasive measures", J Urol, 168, pp.135~138 (2002)
- Jeong SJ, "Prevalence and clinical features of detrusor underactivity among elderly with lower urinary tract symptoms : a comparison between men and women", Korean J Urol, 53, pp.342~348 (2012)
- Gammie A, "Signs and symptoms of detrusor underactivity : an analysis of clinical presentation and urodynamic tests from a large group of patients undergoing pressure flow studies", Eur Urol, 69, pp.361~369 (2016)
- El-Hefnawy AS, "Trigonal-sparing versus trigonal-involved Botox injection for treatment of idiopathic overactive bladder : a randomized clinical trial", Lower Urinary Tract Symptoms, 13, pp.22~30 (2021)
- D’Ancona C, "The International Continence Society(ICS)report on the terminology for adult male lower urinary tract and pelvic floor symptoms and dysfunction", Neurourol Urodyn, 38, pp.433~477 (2019)
- Chapple C, "OnabotulinumtoxinA 100 U Significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence : a randomised, double-Blind, placebo-controlled trial", Eur Urol, 64, pp.249~256 (2013)
- Fowler CJ, "OnabotulinumtoxinA improves health-related quality of life in patients with urinary incontinence due to idiopathic overactive bladder : a 36-week, doubled-blind, placebo-controlled, randomized, dose-ranging trial", Eur Urol, 62, pp.148~157 (2012)
- Cooper AC, "Botox use in the older woman : an advanced bladder treatment option", Curr Geri Rep, 12, pp.28~39 (2023)
- Elbadawi A, "Structural basis of geriatric voiding dysfunction. II. Aging detrusor : normal versus impaired contractility", J Urol, 150, pp.1657~1667 (1993)
- Chancellor MB, "The overactive bladder progression to underactive bladder hypothesis", Int Urol Nephrol, 46(Suppl 1), pp.S23~S27 (2014)
- Yoshida M, "Management of detrusor dysfunction in the elderly : changes in acetylcholine and adenosine triphosphate release during ageing", Urology, 63, pp.17~23 (2004)
- Khera M, "Botulinum toxin A inhibits ATP release from bladder urothelium after chronic spinal cord injury", Neurochem Int, 45, pp.987~993 (2004)
- Matsukawa Y, "Urodynamic evaluation of the efficacy of mirabegron on storage and voiding functions in women with overactive bladder", Urology, 85, pp.786~790 (2015)